US Stock Insider Trading | Enovis Disclosed 1 Company Insider Transaction on March 16

K-LinePoet · 2026-03-25T22:47:36+00:00

On March 16, 2026, Enovis disclosed that executive Engert Oliver purchased 1,000 shares on March 13 at a transaction price of $23.74 per share. Additionally, in recent days, Engert has frequently bought shares, while other executives have conducted selling operations. Enovis is an innovative company focused on medical technology.

K-LinePoet

2026-03-25 22:47:36

Abstract generation in progress

On March 16, 2026, Enovis (ENOV) disclosed a company insider transaction. Executive Oliver Engert purchased 1,000 shares on March 13, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 16, 2026	Executive	Oliver Engert	March 13, 2026	Buy	1,000	23.74	$23,700
March 12, 2026	Executive	Oliver Engert	March 10, 2026	Buy	1,000	23.93	$23,930
March 10, 2026	Executive	Phillip Benjamin Ben Berry	March 7, 2026	Sell	3,167	24.51	$77,600
March 10, 2026	Executive	Terry D. Ross	March 7, 2026	Sell	2,376	24.51	$58,200
March 10, 2026	Executive	John Kleckner	March 7, 2026	Sell	586	24.51	$14,400
March 10, 2026	Executive	Bradley J. Tandy	March 7, 2026	Sell	1,874	24.51	$45,900
March 10, 2026	Executive	Oliver Engert	March 6, 2026	Buy	250	24.28	$6,070
March 10, 2026	Executive	Oliver Engert	March 9, 2026	Buy	1,000	23.39	$23,900
March 10, 2026	Executive	Oliver Engert	March 6, 2026	Buy	500	24.48	$12,200
March 10, 2026	Executive	Louis Vogt	March 7, 2026	Sell	1,980	24.51	$48,500

[Company Profile]

Enovis Corporation was founded in 1995. The company is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions to achieve better patient outcomes and change workflows. Driven by continuous improvement of global talent and an innovative culture, the company’s extensive products, services, and integrated technologies promote active lifestyles in orthopedics and other fields.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.